Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

1.7K
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
1.7K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.6K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.6K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.4K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.4K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

1.1K
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.1K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.8K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Analysis of clinical characteristics of renal oncocytoma: 26 cases report].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2012
Same author

[Expression of Na+/H+ antiporter gene KsNHX1 in Kochia sieversiana under saline-alkali stress].

Ying yong sheng tai xue bao = The journal of applied ecology·2012
Same author

Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice.

International journal of molecular sciences·2012
Same author

[Analysis of genes and genetic susceptibility of olfactory disorders].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2012
Same author

Top-down processing of symbolic meanings modulates the visual word form area.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2012
Same author

Oxidative stress acts on special membrane proteins to reduce the viability of Pseudomonas syringae pv tomato.

Journal of proteome research·2012

Related Experiment Videos

Baclofen for alcohol withdrawal.

Jia Liu1, Lu-Ning Wang

  • 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Changchun Street 45, Beijing, China, 100053.

The Cochrane Database of Systematic Reviews
|April 4, 2015
PubMed
Summary
This summary is machine-generated.

Baclofen shows potential for treating alcohol withdrawal syndrome (AWS), but current evidence is insufficient. More high-quality randomized controlled trials are needed to confirm its efficacy and safety for AWS patients.

Related Experiment Videos

Area of Science:

  • Pharmacology
  • Neurology
  • Addiction Medicine

Background:

  • Alcohol withdrawal syndrome (AWS) is a serious condition requiring effective treatment.
  • Baclofen is being investigated as a potential treatment for AWS due to its safety profile and ease of management.
  • This review is an update of previous research on baclofen for AWS.

Purpose of the Study:

  • To evaluate the effectiveness and safety of baclofen in managing alcohol withdrawal syndrome (AWS).

Main Methods:

  • Systematic search of multiple electronic databases and trial registries up to January 2015.
  • Inclusion of randomized controlled trials (RCTs) comparing baclofen with placebo or other treatments for AWS.
  • Independent assessment of studies and data collection on efficacy and adverse effects.

Main Results:

  • Two RCTs with 81 participants were included.
  • One study indicated baclofen and diazepam similarly reduced AWS symptoms (CIWA-Ar scores).
  • Another study found baclofen did not significantly alter CIWA-Ar scores compared to placebo but reduced benzodiazepine dependence.

Conclusions:

  • Current evidence is insufficient to recommend baclofen for alcohol withdrawal syndrome (AWS).
  • Further well-designed randomized controlled trials are necessary to establish the efficacy and safety of baclofen for AWS.